BRIEF-AttrubyA Approved By FDA To Reduce Cardiovascular Death And Cardiovascular-Related Hospitalization In Attr-Cm Patients

Reuters08:18

Nov 22 (Reuters) - BridgeBio Pharma Inc BBIO.O:

ATTRUBY™ (ACORAMIDIS), A NEAR COMPLETE TTR STABILIZER (≥90%), APPROVED BY FDA TO REDUCE CARDIOVASCULAR DEATH AND CARDIOVASCULAR-RELATED HOSPITALIZATION IN ATTR-CM PATIENTS
BRIDGEBIO PHARMA INC - FDA APPROVES ATTRUBY FOR TREATMENT OF ATTR-CM
BRIDGEBIO PHARMA INC - TO RECEIVE $500 MILLION PAYMENT UNDER ROYALTY AGREEMENT
BRIDGEBIO PHARMA INC - GRANTS BAYER RIGHTS TO COMMERCIALIZE ACORAMIDIS IN EUROPE

Source text: ID:nGNXcbblpf

Further company coverage: BBIO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485249752?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-23 08:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485249752","market":"us","top_or_hot":-1,"title":"BRIEF-AttrubyA Approved By FDA To Reduce Cardiovascular Death And Cardiovascular-Related Hospitalization In Attr-Cm Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-AttrubyA Approved By FDA To Reduce Cardiovascular Death And Cardiovascular-Related Hospitalization In Attr-Cm Patients</title></head><body><p><span>Nov 22 (Reuters)</span><span> - </span>BridgeBio Pharma Inc <span>BBIO.O</span>:</p><ul><li><p>ATTRUBY™ (ACORAMIDIS), A NEAR COMPLETE TTR STABILIZER (≥90%), APPROVED BY FDA TO REDUCE CARDIOVASCULAR DEATH AND CARDIOVASCULAR-RELATED HOSPITALIZATION IN ATTR-CM PATIENTS</p></li><li><p>BRIDGEBIO PHARMA INC - FDA APPROVES ATTRUBY FOR TREATMENT OF ATTR-CM</p></li><li><p>BRIDGEBIO PHARMA INC - TO RECEIVE $500 MILLION PAYMENT UNDER ROYALTY AGREEMENT</p></li><li><p>BRIDGEBIO PHARMA INC - GRANTS BAYER RIGHTS TO COMMERCIALIZE ACORAMIDIS IN EUROPE</p></li></ul><p>Source text: <span>ID:nGNXcbblpf</span></p><p>Further company coverage: <span>BBIO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-AttrubyA Approved By FDA To Reduce Cardiovascular Death And Cardiovascular-Related Hospitalization In Attr-Cm Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-AttrubyA Approved By FDA To Reduce Cardiovascular Death And Cardiovascular-Related Hospitalization In Attr-Cm Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-23 08:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241123:nTUABMSNLK:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-AttrubyA Approved By FDA To Reduce Cardiovascular Death And Cardiovascular-Related Hospitalization In Attr-Cm PatientsNov 22 (Reuters) - BridgeBio Pharma Inc BBIO.O:ATTRUBY™ (ACORAMIDIS), A NEAR...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241123:nTUABMSNLK:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241123:nTUABMSNLK:1","article_id":"2485249752","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485249752","pubTimestamp":1732321105,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-AttrubyA Approved By FDA To Reduce Cardiovascular Death And Cardiovascular-Related Hospitalization In Attr-Cm PatientsNov 22 (Reuters) - BridgeBio Pharma Inc BBIO.O:ATTRUBY (ACORAMIDIS), A NEAR ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股","BBIO":"BridgeBio Pharma, Inc."},"translate_title":"BRIEF-AttrubyA获FDA批准可减少Attr-Cm患者的心血管死亡和心血管相关住院","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBIO":0.9},"content_text":"BRIEF-AttrubyA Approved By FDA To Reduce Cardiovascular Death And Cardiovascular-Related Hospitalization In Attr-Cm PatientsNov 22 (Reuters) - BridgeBio Pharma Inc BBIO.O:ATTRUBY™ (ACORAMIDIS), A NEAR COMPLETE TTR STABILIZER (≥90%), APPROVED BY FDA TO REDUCE CARDIOVASCULAR DEATH AND CARDIOVASCULAR-RELATED HOSPITALIZATION IN ATTR-CM PATIENTSBRIDGEBIO PHARMA INC - FDA APPROVES ATTRUBY FOR TREATMENT OF ATTR-CMBRIDGEBIO PHARMA INC - TO RECEIVE $500 MILLION PAYMENT UNDER ROYALTY AGREEMENTBRIDGEBIO PHARMA INC - GRANTS BAYER RIGHTS TO COMMERCIALIZE ACORAMIDIS IN EUROPESource text: ID:nGNXcbblpfFurther company coverage: BBIO.O ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485249752"}